Literature DB >> 311245

Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate.

S B Howell, A Krishan, E Frei.   

Abstract

The cytokinetics of marrow recovery were compared in patients receiving a standard exposure to high-dose methotrexate followed by either thymidine rescue, leucovorin rescue at the doses used in most clinical protocols (10 mg/sq m every 6 hr), or leucovorin rescue at a 5-fold higher dose rate (50 mg/sq m every 6 hr). Thymidine rescue initiated a prompt recovery of DNA synthesis, as detected by [3H]deoxycytidine incorporation, and progression of cells through the cell cycle monitored by flow cytometry, even in the presence of methotrexate levels that prevented initiation of rescue by the lower doses of leucovorin. Dose dependency for leucovorin in vivo in humans was suggested by the observation that the higher leucovorin dose rate was successful in initiating recue within the first 24 hr, whereas the lower dose was not. Recovery of DNA synthesis is more rapid and/or complete with thymidine rescue than with either dose of leucovorin. Thymidine rescue was accomplished without requirement for purines over and above those present in plasma. These results suggest that the kinetics of marrow recovery is quite different for thymidine and leucovorin rescue.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 311245

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Flow cytometric analysis of marrow cell kinetics in children treated with high-dose MTX and CF rescue.

Authors:  M Tsurusawa; K Sasaki; H Matsuoka; Y Yamamoto; N Katano; T Fujimoto
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.

Authors:  S B Howell; B B Chu; W E Wung; B M Metha; J Mendelsohn
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

3.  Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate.

Authors:  S B Howell; S J Mansfield; R Taetle
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 4.  Thymidine as an anticancer agent, alone or in combination. A biochemical appraisal.

Authors:  P H Ellims
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

5.  Methotrexate cytotoxicity as related to irreversible S phase arrest in mouse L1210 leukemia cells.

Authors:  M Tsurusawa; M Niwa; N Katano; T Fujimoto
Journal:  Jpn J Cancer Res       Date:  1990-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.